IONS
Ionis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$58.09
−0.07%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 873.8M | 944.0M | 705.1M | 787.6M | 587.4M |
| Cost of Revenue | 16.1M | 16.0M | 11.2M | 9.1M | 14.1M |
| Gross Profit | 857.7M | 928.0M | 693.9M | 778.5M | 573.3M |
| Operating Expenses | |||||
| R&D Expense | 925.0M | 916.0M | 901.5M | 899.6M | 833.0M |
| SG&A Expense | 527.6M | 394.0M | 267.5M | 232.6M | 150.3M |
| General & Admin Expense | 96.8M | — | 267.5M | 232.6M | 150.3M |
| Selling & Marketing Expense | — | — | — | — | (5.0K) |
| Other Expenses | 9.0K | — | (26.0K) | 19.0K | 147.0K |
| Total Operating Expenses | 1.5B | 1.3B | 1.2B | 1.1B | 983.4M |
| Cost and Expenses | 1.5B | 1.3B | 1.2B | 1.1B | 997.6M |
| Operating Income (EBIT) | (594.9M) | (382.0M) | (475.1M) | (353.7M) | (410.2M) |
| Non-Operating | |||||
| Interest Income | 94.1M | 97.8M | 107.0M | 89.0M | 25.3M |
| Interest Expense | 89.5M | 90.5M | 90.5M | 81.5M | 8.1M |
| Net Interest Income | 4.7M | 7.2M | 16.6M | 7.6M | 17.2M |
| Other Non-Op Income/Expense | 32.8M | 2.0M | 15.0M | 19.8M | 152.2M |
| Non-Operating Income (excl Interest) | (93.0M) | (75.0M) | (99.4M) | (95.4M) | (160.3M) |
| EBT (Pre-Tax Income) | (562.1M) | (380.0M) | (460.1M) | (334.0M) | (258.0M) |
| Income Tax Expense | 167.0K | 1.0M | (6.2M) | 32.3M | 11.7M |
| Bottom Line | |||||
| Net Income | (564.8M) | (381.0M) | (453.9M) | (366.3M) | (269.7M) |
| Earnings from Cont. Ops | (562.3M) | (381.0M) | (453.9M) | (366.3M) | (269.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (564.8M) | (381.0M) | (453.9M) | (366.3M) | (269.7M) |
| Per Share | |||||
| Basic EPS | ($3.46) | ($2.38) | ($3.04) | ($2.56) | ($1.90) |
| Diluted EPS | ($3.46) | ($2.38) | ($3.04) | ($2.56) | ($1.90) |
| Revenue Per Share | $5.28 | $5.90 | $4.72 | $5.51 | $4.14 |
| Shares | |||||
| Basic Shares Outstanding | 165.4M | 160.0M | 149.5M | 143.0M | 141.8M |
| Diluted Shares Outstanding | 165.4M | 160.0M | 149.5M | 143.2M | 141.8M |
| Profitability Metrics | |||||
| EBITDA | 4.3B | (286.7M) | (353.7M) | (235.9M) | (227.8M) |
| D&A | 4.8B | 20.3M | 22.0M | 22.5M | 22.1M |
| EBIT | (501.9M) | (307.0M) | (375.7M) | (258.4M) | (249.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026